Previous 10 | Next 10 |
2023-07-05 00:51:54 ET Summary ANIP Pharmaceuticals has not yet published a pipeline of products under development or out-licensed, leaving investors in the dark about future revenue opportunities. The company has a range of drugs in various stages of development, including treatm...
2023-05-30 21:12:20 ET Summary ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. The company has a diverse product portfolio and strong relationships in the generic drug market. Despite high debt levels, ANI Pharmaceut...
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive o...
2023-05-15 07:15:14 ET Shares of ANI Pharmaceuticals ( NASDAQ: ANIP ) spiked in the pre-market Monday after announcing that the FDA approved the market entry of the company’s generics for seizure therapy Celontin and osteoporosis drug RLD Fosamax Oral Solution. In approvi...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuxi...
2023-05-12 07:37:34 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) prices public offering of 1.9M shares at a public offering price of $39.50 per share. Gross proceeds are expected to be $75M. Underwriters a 30-day option to purchase up to an additional 284.8K shares. ...
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock at a public offering price of $39.50 per share. The gross proceeds of the offering to the Co...
2023-05-11 17:45:25 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) on Thursday announced a proposed stock offering. Shares of ANIP slipped 6% to $41.30 after hours. The company will offer all the shares to be sold in the offering. ANI said it would use the net proceed...
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and th...
2023-05-08 13:35:19 ET ANI Pharmaceuticals, Inc. (ANIP) Q1 2023 Earnings Conference Call May 8, 2023, 8:30 AM ET Company Participants Judy DiClemente - Insight Communications Investor Relations Nikhil Lalwani - President and CEO Stephen Carey - Chief Financial Of...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....
PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year ® 2024 New Jersey Award winner. Entr...
2024-06-24 08:08:29 ET Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sc...